Legend Biotech (LEGN) Consolidated Net Income (2019 - 2026)
Legend Biotech's (LEGN) quarterly Consolidated Net Income came in at -$55.0 million in Q1 2026, up 45.54% YoY from -$37.8 million in Q1 2025, and down 77.99% on a QoQ basis from -$30.9 million in Q4 2025.
Legend Biotech (LEGN) Consolidated Net Income (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Consolidated Net Income data on file, last reported at -$55.0 million in Q1 2026.
- Quarterly Consolidated Net Income rose 45.54% year-over-year to -$55.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$248.6 million (down 6.98% YoY) and the FY2025 annual result came in at -$296.8 million, down 51.48% from the prior year.
- Consolidated Net Income fell to -$55.0 million in Q1 2026, from -$30.9 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $2.8 million in Q4 2024 to a low of -$198.5 million in Q2 2023.
- A 5-year average of -$88.6 million and a median of -$85.6 million in 2022 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2022 — Consolidated Net Income tumbled 32288.91% — and 2024, when it surged 101.95%.
- Tracing LEGN's Consolidated Net Income over 5 years: stood at -$136.0 million in 2022, then slipped by 6.65% to -$145.0 million in 2023, then surged by 101.95% to $2.8 million in 2024, then sank by 1190.33% to -$30.9 million in 2025, then plunged by 77.99% to -$55.0 million in 2026.
- The last three Consolidated Net Income figures came in at -$55.0 million (Q1 2026), -$30.9 million (Q4 2025), and -$38.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 33.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.20 Mn |
| Mar 31, 2026 | -55.00 Mn |
| Dec 31, 2025 | -30.90 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.22 Mn |
| Mar 31, 2025 | -101.00 Mn |
| Dec 31, 2024 | 2.83 Mn |
| Sep 30, 2024 | -116.45 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Mar 31, 2024 | -59.78 Mn |
| Dec 31, 2023 | -145.04 Mn |
| Sep 30, 2023 | -62.78 Mn |
| Jun 30, 2023 | -198.55 Mn |
| Mar 31, 2023 | -111.85 Mn |
| Dec 31, 2022 | -136.00 Mn |
| Sep 30, 2022 | -85.62 Mn |
| Jun 30, 2022 | -192.91 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -84.72 Mn |
| Sep 30, 2021 | -124.75 Mn |